The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The summit comes amid fears over a global economic slowdown, and U.S. tensions over trade allies, Iran and Russia.Politicsread more
The world's second biggest economy is past a point where it cannot ignore its enormous debt anymore, according to an analyst.China Economyread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
Trump does have some powerful tools that would not require approval from U.S. Congress.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
As demand for lab monkeys continues to rise, U.S. scientists are reporting delays in research projects because they can't obtain enough animals, according to the National...Politicsread more
The European Union will respond in kind if the U.S. imposes tariffs on France over digital tax plan, EU chief Donald Tusk told G-7.Technologyread more
Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
ASCO, the world's largest cancer research conference, starts Friday in Chicago, where oncologists, investors and pharmaceutical executives converge to discuss the latest advancements in treatment.
Immunotherapies, medicines that enable the immune system to better fight cancer, will continue to be a top focus of the conference. Merck, Bristol-Myers, Roche, AstraZeneca, Pfizer and others are working in the space, which BMO Capital Markets analyst Alex Arfaei estimates may be worth $30 billion by 2020. The cost to treat cancer is sure also to be a major topic.
But it's the smaller companies that often see the biggest stock moves out of ASCO (which stands for the American Society of Clinical Oncology). Already the Nasdaq Biotech Index has rallied into the conference, gaining 6 percent in the last five days. Yet many analysts say this year's meeting looks to be a slower one from an investment perspective. So we decided to ask Kensho, a market data analytics system, what history tells us to expect from ASCO stock performance.
Looking at ASCO meetings since 2011, and a lengthy list of presenting companies with market values of at least $1 billion from a JPMorgan research note, here's what we found:
The most consistently positive performers out of ASCO are Seattle Genetics, Regeneron, Ariad, Ionis Pharmaceuticals and Halozyme Therapeutics, which traded up at least four years out of the last five (or 80 percent of the time). That's if investors bought the stock the first day of the conference and sold a week afterwards.
Some of those companies will be closely watched at this year's conference as well: Ariad, for new data on its experimental lung cancer drug, brigatinib, and Seattle Genetics, both for data from a competitor in Hodgkin's lymphoma and for one of its internal programs in urothelial cancer, according to RBC Capital Markets.
Another way to track stock performance out of ASCO is a relatively new exchange-traded fund focused exclusively on companies working in immunotherapy, the CNCR Immunotherapy ETF. Started by investor Brad Loncar, it's also rallied into the conference, returning more than 13 percent since initial datasets were released ahead of the conference May 18.
(Source: Loncar Investments. Data as of Thursday's close.)
As for biotech stocks more broadly, Kensho tells us the IBB, the ETF that tracks the Nasdaq Biotech Index, historically only slightly outperforms the broader market through ASCO, returning an average of 0.64 percent from the first day of the conference to a week later, versus 0.56 percent for the .
Disclosure: NBCUniversal, parent of CNBC, is aminority investor in Kensho.